ETFs Qiagen N.V.

QGEN

NL0015002CX3

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2025-12-15 pm EST			5-day change	1st Jan Change
45.44 ^USD	+0.49%		-3.34%	-0.79%

Dec. 15	Qiagen raises EPS estimates despite FX headwinds
Dec. 11	Citigroup Downgrades QGEN to Neutral From Buy, Price Target is $55	MT

ETFs positioned on Qiagen N.V.

Name	Weight	AuM	Varia. Jan 1.	Investor
FIRST TRUST NYSE ARCA BIOTECHNOLOGY ETF - CAD	3.1%	1 M€	0.00%	-
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED	1.65%	2 M€	+9.31%	-
GLOBAL X ROBO GLOBAL ROBOTICS & AUTOMATION ETF - AUD	1.32%	148 M€	+17.07%	-
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD	1.08%	5 M€	0.00%	-
LEVERAGE SHARES -3X SHORT GERMANY 40 ETP SECURITIES - EUR	0.91%	1 M€	0.00%	-
LEVERAGE SHARES 3X LONG GERMANY 40 ETP SECURITIES - EUR	0.91%	1 M€	+54.63%	-
LYXOR CORE DAX (DR) UCITS ETF - EUR	0.81%	962 M€	-.--%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	0.38%	26 M€	+11.49%	-
HARTFORD MULTIFACTOR DEVELOPED MARKETS (EX-US) ETF - USD	0.17%	1,096 M€	+30.75%	-
UBS (IRL) ETF PLC MSCI EUROPE ESG UNIVERSAL LOW CARBON SELECT UCITS ETF - ACC - EUR	0.08%	0 M€	-.--%	-
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF	0.04%	33,076 M€	+20.52%	-
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR INTERNATIONAL ETF - USD	0.04%	32 M€	+26.20%	-
AMUNDI MSCI WORLD CLIMATE TRANSITION CTB - UCITS ETF DR (C) - USD	0.02%	0 M€	-.--%	-
LYXOR MSCI WORLD CLIMATE CHANGE (DR) UCITS ETF - ACC - USD	0.02%	0 M€	-.--%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (UNHEDGED) ETF - JPY	0.02%	386 M€	+15.50%	-
AMUNDI MSCI WORLD CLIMATE PARIS ALIGNED PAB UCITS ETF DR (C) - USD	0.02%	0 M€	-.--%	-
LYXOR NET ZERO 2050 S&P WORLD CLIMATE PAB (DR) UCITS ETF - ACC - USD	0.02%	0 M€	-.--%	-
AMUNDI INDEX MSCI WORLD - UCITS ETF DR (C) - EUR	0.02%	0 M€	-.--%	-
AMUNDI INDEX MSCI WORLD UCITS ETF DR (D) - EUR	0.02%	0 M€	-.--%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0.02%	839 M€	+6.24%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.02%	62 M€	+5.67%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR	0.01%	619 M€	+6.03%	-

1 2

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Employees

5,700

Sector

Biotechnology & Medical Research

Calendar

Feb. 09 - Q4 2025 Earnings Release (Projected)

More about the company